Surgery is the standard of care for resectable solid tumors.
Loco-regional approaches, in combination with chemotherapy and/or radiotherapy, are standard therapy in the following settings:
In the presence of a combination of systemic chemotherapy, radiotherapy and loco-regional is the standard approach, whereby radiotherapy can trigger an anti-cancer immune response that can be further exploited by the new immune-stimulator drugs.
Controlled administration of radionuclides falls in the field of loco-regional therapies for the treatment of tumors. Administration of β-emitting radionuclides vs external radiotherapy presents several advantages: high radiation dose delivery (improved efficacy), low surrounding tissue penetration, low impact on blood vessels, high control of administered energy (limited side effects).
Radiation therapy based on β-emitting microspheres is currently approved in the clinical practice only for intra-arterial administration in hepatic tumors (with proven safety and efficacy); multiple work-up procedures are needed to avoid unwanted diffusion of radionuclides in the adjacent organs.
Radionuclides are administered through a proprietary device engineered to guarantee a precise delivery of the required dose of energy where it is needed, thus overcoming some disadvantages of external beam radiation therapy (EBRT).
Applications of this β-emitting radiotherapy platform vary from the intra-tumoral treatment of unresectable or metastatic tumors, to the treatment of surgical margins after tumor excision to avoid local recurrences. Additional applications are in the prevention of complications following lung/liver biopsies, or other loco-regional treatments.
via San Primo 4
I-20121 Milano, Italy